Welcome to our dedicated page for Yulong Eco-Matls news (Ticker: YECO), a resource for investors and traders seeking the latest updates and insights on Yulong Eco-Matls stock.
EV Biologics Corp (YECO) is a pioneering biotechnology company advancing stem cell-derived exosome therapeutics and nanoparticle-based biologics for regenerative medicine. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access verified information about YECO's biomanufacturing innovations, including Excyte subsidiary advancements and EcoCura™ product developments. Our curated news collection covers FDA filings, research collaborations, intellectual property updates, and biocompatible formulation breakthroughs – all essential for tracking progress in longevity therapeutics.
Bookmark this page for direct access to EV Biologics' official press releases, financial disclosures, and peer-reviewed research announcements. Stay informed about emerging applications of their nanotherapeutic platforms in age-related diseases and tissue regeneration through our comprehensive updates.
EV Biologics Corp (OTC PINK: YECO) has successfully isolated primary progenitor cells using a xeno-free process, aimed at creating cell banks for therapeutic nanoparticle production. The company is focusing on optimizing this process to comply with Good Manufacturing Practice (GMP). The initial nanoparticle therapeutics are expected to be produced by Q2 2023. CEO Daniel Mckinney emphasizes the goal of enhancing shareholder value through innovative nanotherapeutics targeting regenerative medicine. YECO has 7.22 million shares outstanding, with a float of 1,016,375 shares.
EV Biologics Corp (OTC PINK: YECO) updated shareholders on March 9, 2022, regarding its FINRA applications for a name change and NFT dividend distribution. The name change process has stalled as FINRA requires the company to become fully SEC reporting, which would divert resources from its focus on biomanufacturing innovations. Additionally, the planned NFT dividend distribution is suspended due to regulatory challenges. The company is emphasizing its development of nanomedicines and AI-driven biological data systems.
EV Biologics Corp (OTC PINK:YECO) has updated shareholders regarding its pending FINRA applications for an NFT dividend distribution and name change. The company is awaiting FINRA's approval for its unique NFT dividend, which would mark the first such distribution by a public company. Shareholders of record from July 30, 2021, will receive a warrant to own the NFT. The name change process has experienced delays since August 2020. EV Biologics is transitioning to digital securities and plans to list on the INX exchange, focusing on nanomedicine and regenerative therapies.
EV Biologics Corp (YECO) provided an update on its NFT dividend, awaiting FINRA approval for distribution. Shareholders of record as of July 30, 2021, are eligible to receive one Warrant for every 100 shares held, with each Warrant entitling them to an NFT valued at $300. The company has minted 72,253 NFTs, marking a significant achievement in the NFT space. The NFT, named rEVerie, symbolizes advancements in extracellular vesicle technology. No dividend date has been confirmed yet.
EV Biologics Corp (OTC PINK: YECO) announced its agreement to list its common stock on the INX Securities ATS, a regulated trading platform. This approval follows due diligence and aims to enhance the value of the company's shares, which have suffered from naked short selling. CEO Daniel McKinney emphasized the company's low market cap compared to peers and its ambition to lead the biotech sector in 12-24 months. The firm plans to transition to digital securities on the blockchain, making short selling and naked shorting practically impossible.
EV Biologics Corp, trading under OTC Pink:YECO, has provided an update on a publication by Chief Medical Officer Dr. Jason Sanders, discussing the role of small extracellular vesicles (EVs) in COVID-19 treatment. The review highlights therapeutic potentials of mesenchymal stem cell (MSC) exosomes for Acute Lung Injury (ALI). Dr. Sanders emphasizes ongoing advancements in EV-based therapeutics. The company is focused on developing optimized clonal stem cell lines for FDA-approved biomanufactured drugs targeting various clinical conditions, including autoimmune and degenerative diseases.
EV Biologics Corp (OTC PINK: YECO) has provided a shareholder update on its NFT project, revealing that it is minting 72,253 NFTs titled rEVerie, which is anticipated to be the largest NFT minting in history. The NFTs will serve as a dividend for shareholders of record as of July 30, 2021. Each shareholder will receive one warrant for every 100 shares owned, entitling them to an NFT valued at $300. The distribution is pending FINRA approval, and shareholders have until December 1, 2021, to exercise their warrants.
EV Biologics Corp (OTC Pink: YECO) has announced the upcoming distribution of its NFT Warrant Dividend. Shareholders-of-record as of July 30, 2021, will receive one Warrant for every 100 shares held, each exercisable for an NFT valued at $300. The company is finalizing its filing with FINRA and will proceed with the dividend distribution through DTC. Shareholders have until December 1, 2021, to exercise their Warrants. Currently, YECO has approximately 7.22 million shares outstanding, with a float of 1,016,375 shares.
EV Biologics Corp (OTC Pink: YECO) has updated shareholders on its market capitalization in comparison to peers, highlighting that its value is less than half that of its closest competitor. The company aims to increase its market cap by 20 times within the next 24 months. In its quarterly report for June 30, 2021, EV Biologics reported $600,000 in cash, recent revenue, and a fully funded $5 million line of credit for biomanufacturing development. The firm plans to up-list to OTCQX by year's end.
EV Biologics Corp (OTC PINK: YECO) announced a NFT Warrant Dividend for shareholders on July 30, 2021. Shareholders will receive one Warrant for every 100 shares held, allowing them to claim an NFT valued at $300. The deadline to exercise these Warrants is December 1, 2021. The CEO, Daniel Mckinney, emphasized the artistic quality of the NFT, related to the Company’s paracrine therapeutics development. Shareholders who do not receive their Warrants by the end of August should contact their brokers or FINRA if their shares were loaned for short sales. YECO has 7.22 million shares outstanding.
